S&P 500 may face selling pressure as systematic funds reach full exposure
NEW YORK -On Friday, Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) reported fourth-quarter revenue that beat analyst expectations and provided strong guidance for 2025.
The company’s shares gained 2.63% in premarket trading after the results.
The generic and specialty pharmaceutical company posted Q4 revenue of $731 million, surpassing the consensus estimate of $703.74 million. Revenue increased 18% year-over-year, driven by growth across all three business segments.
Adjusted earnings per share came in at $0.12, missing analyst projections of $0.15.
For full-year 2025, Amneal forecasts revenue between $3 billion and $3.1 billion, above Wall Street’s expectation of $2.92 billion. The company expects adjusted EPS of $0.65 to $0.70, compared to the $0.71 consensus estimate.
"Amneal’s continued success in 2024 demonstrates our ability to drive sustainable growth through disciplined execution, continuous innovation, and strategic capital allocation," said Co-CEOs Chirag and Chintu Patel in a statement.
The company highlighted double-digit revenue growth in its Affordable Medicines, AvKARE, and Specialty segments. Amneal also noted it successfully launched CREXONT and reduced net leverage to 3.9x, one year ahead of its commitment.
While earnings fell short of estimates, investors appear focused on the strong top-line performance and optimistic outlook, sending shares higher in early trading.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.